About Enanta Pharmaceuticals, Inc.
https://www.enanta.comEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
CEO
Jay R. Luly
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Jefferies
Buy
WestPark Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:2.12M
Value:$28.33M
KRENSAVAGE ASSET MANAGEMENT, LLC
Shares:2.11M
Value:$28.23M
JANUS HENDERSON GROUP PLC
Shares:1.95M
Value:$25.99M
Summary
Showing Top 3 of 164
About Enanta Pharmaceuticals, Inc.
https://www.enanta.comEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $15.13M ▼ | $33.51M ▼ | $-18.7M ▼ | -123.64% ▼ | $-0.87 ▼ | $-16.28M ▼ |
| Q3-2025 | $18.31M ▲ | $37.21M ▼ | $-18.25M ▲ | -99.68% ▲ | $-0.85 ▲ | $-15.4M ▲ |
| Q2-2025 | $14.93M ▼ | $39.45M ▼ | $-22.64M ▼ | -151.71% ▼ | $-1.06 ▼ | $-21.03M ▼ |
| Q1-2025 | $16.96M ▲ | $40.5M ▼ | $-22.29M ▲ | -131.43% ▲ | $-1.05 ▲ | $-19.86M ▲ |
| Q4-2024 | $14.61M | $44.46M | $-28.82M | -197.32% | $-1.36 | $-26.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $188.86M ▼ | $280.73M ▼ | $216.01M ▼ | $64.72M ▼ |
| Q3-2025 | $204.11M ▲ | $301.03M ▼ | $221.75M ▼ | $79.28M ▼ |
| Q2-2025 | $193.38M ▼ | $322.99M ▼ | $229.46M ▼ | $93.54M ▼ |
| Q1-2025 | $216.69M ▼ | $348.64M ▼ | $236.83M ▼ | $111.82M ▼ |
| Q4-2024 | $248.19M | $376.65M | $247.84M | $128.81M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.25M ▲ | $17.51M ▲ | $-26.48M ▼ | $-6.42M ▲ | $-15.4M ▲ | $17.35M ▲ |
| Q2-2025 | $-22.64M ▼ | $-13.49M ▲ | $-4.37M ▼ | $-6.89M ▼ | $-24.74M ▼ | $-16.03M ▲ |
| Q1-2025 | $-22.29M ▲ | $-16.8M ▼ | $68.9M ▲ | $-4.99M ▲ | $47.12M ▲ | $-25.55M ▼ |
| Q4-2024 | $-28.82M ▼ | $-10.4M ▲ | $19.07M ▲ | $-7.21M ▼ | $1.46M ▲ | $-19.35M ▲ |
| Q3-2024 | $-22.66M | $-14.78M | $-6.34M | $-6.65M | $-27.77M | $-21.32M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 Royalty | $20.00M ▲ | $10.00M ▼ | $20.00M ▲ | $20.00M ▲ |
CEO
Jay R. Luly
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Jefferies
Buy
WestPark Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Evercore ISI Group
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:2.12M
Value:$28.33M
KRENSAVAGE ASSET MANAGEMENT, LLC
Shares:2.11M
Value:$28.23M
JANUS HENDERSON GROUP PLC
Shares:1.95M
Value:$25.99M
Summary
Showing Top 3 of 164